Shareholders in Spero Therapeutics (NASDAQ:SPRO) Are in the Red If They Invested Three Years Ago

Yahoo FinanceMay 10 19:05

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatm

GlobeNewswireMay 8 20:00

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare

GlobeNewswireMay 2 04:07

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics with a Overweight.

Analyst UpgradesApr 4 21:45

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics with a Buy and maintains $7 price target.

Analyst UpgradesMar 18 19:02

Spero Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/18/2024 300% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $7 Rei

BenzingaMar 18 19:01